Clinical trials: Vascular And Immunologic Diseases
Multiple Myeloma
D.T. PACE Versus High Dose Melphalan and Autologous Transplant in Patients With Previously Treated Multiple Myeloma
This study has been designed to evaluate whether combination chemotherapy and "anti-angiogenesis" therapy with thalidomide is equal or superior to autologous transplantation for the treatment of multiple myeloma.
- Trial name
- NCT00083876
- Testing
- Thalidomide
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- University of Arkansas
Chronic Lymphocytic Leukemia, Atrial Fibrillation
Hypertension and Arrhythmias in CLL Patients Treated With BTK Inhibitors
Acalabrutinib and Zanabrutinib are highly effective drugs used to treat Chronic Lymphocytic Leukemia, but they are associated with high blood pressure and abnormal heart rhythms.
- Conditions
- Chronic Lymphocytic Leukemia, Atrial Fibrillation, Hypertension, Cardiotoxicity
- Trial name
- SENTINEL (NCT06211413)
- Testing
- no intervention
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
A Trial of Selinexor, Ruxolitinib and Methylprednisolone
Selinexor, a first-in-class, oral selective exportin 1 (XPO1) inhibitor, has shown promise in pre-clinical and clinical studies.
- Trial name
- KPT-IST-391 (NCT06225310)
- Testing
- Selinexor, Ruxolitinib, Methylprednisolone
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Oncotherapeutics
Multiple Myeloma
LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple Myeloma
The study drug elotuzumab, has been clinically shown to be effective in treating relapsed/refractory MM in combination with either bortezomib, or lenalidomide and dexamethasone.
- Trial name
- NCT03361306
- Testing
- Elotuzumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Wake Forest University Health Sciences
Sinus Disease, EGPA - Eosinophilic Granulomatosis With Polyangiitis
Effectiveness on Sino-Nasal Symptoms Of Mepolizumab 300
OBJECTIVES The primary objective of this study is evaluating the reduction of dimension of nasal polyps measured with Nasal Polyp Endoscopic Score (NPS) The secondary objective is to evaluate the improvement in nasal symptoms and…
- Conditions
- Sinus Disease, EGPA - Eosinophilic Granulomatosis With Polyangiitis, Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps
- Trial name
- MEPO300REAL (NCT07592104)
- Testing
- Mepolizumab 300 mg
- Where
- Italy
- Volunteers
- 52 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Hematological Malignancies
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to evaluate the efficacy and safety of talquetamab in participants with relapsed or refractory multiple myeloma at the recommended Phase 2 dose(s) (RP2Ds) (Part 3).
- Trial name
- MonumenTAL-1 (NCT04634552)
- Testing
- Talquetamab
- Where
- 78 sites in United States, Belgium and 9 more
- Volunteers
- 510 people
- Sponsor
- Janssen Research & Development, LLC
Waldenstrom Macroglobulinemia
Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM
The purpose of this study is to determine the very good partial response (VGPR) or better rate in participants with Waldenström macroglobulinemia (WM).
- Trial name
- ZEBRA (NCT06561347)
- Testing
- Zanubrutinib, Bendamustine, Rituximab
- Where
- 5 sites in United States
- Volunteers
- 65 people
- Sponsor
- Massachusetts General Hospital
Multiple Myeloma of Bone
Predicting Response to Selinexor-Based Therapy in Relapsed/Refractory Multiple Myeloma: A Multicenter Prospective Study
Background: Relapsed/refractory multiple myeloma (RRMM) remains a major clinical challenge due to treatment resistance and disease heterogeneity.
- Trial name
- NCT07514052
- Testing
- Selinexor-Based Regimen
- Where
- China
- Volunteers
- 127 people
- Sponsor
- Shanxi Bethune Hospital
Chronic Myeloproliferative Disorders, Cognitive/Functional Effects
Registry of Older Patients With Cancer
RATIONALE: Gathering information about older patients with cancer may help the study of cancer in the future. PURPOSE: This research study is gathering information from older patients with cancer into a registry.
- Conditions
- Chronic Myeloproliferative Disorders, Cognitive/Functional Effects, Leukemia, Lymphoma
- Trial name
- NCT01137825
- Where
- 7 sites in United States
- Volunteers
- 3,000 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Multiple Myeloma
Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma
Multiple myeloma (MM) is a common incurable blood cancer causing debilitating symptoms-bone pain, kidney failure, low blood counts and infection.
- Trial name
- NCT02331368
- Testing
- Autologous Stem Cell Transplant, Melphalan, Lenalidomide
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- University of Michigan Rogel Cancer Center
Multiple Myeloma and Plasma Cell Neoplasm
Melphalan, Prednisone, and Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
RATIONALE: Drugs used in chemotherapy, such as melphalan, prednisone, and lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00477750
- Testing
- lenalidomide, melphalan, prednisone
- Where
- 3 sites in United States
- Volunteers
- 33 people
- Sponsor
- Mayo Clinic
Angioedema
Lanadelumab in Long-term Prophylaxis of Acquired Angioedema
use of lanadelumab in patients with acquired angioedema
- Trial name
- NCT06818474
- Testing
- Lanadelumab 300 mg
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Bernstein Clinical Research Center
Multiple Myeloma
A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma
The purpose of Part 1 of the study is to determine the safety of the combination of Siltuximab (CNTO 328) and bortezomib (Velcade).
- Trial name
- NCT00401843
- Testing
- Siltuximab, Bortezomib, Dexamethasone
- Where
- 80 sites in United States, Belgium and 16 more
- Volunteers
- 307 people
- Sponsor
- Janssen Research & Development, LLC
Rheumatoid Arthritis, Autoimmune Rheumatologic Disease
COvid-19 Vaccine Booster in Immunocompromised Rheumatic Diseases
People living with Systemic autoimmune rheumatic diseases (SARDs) face a new and urgent dilemma: immunosuppression increases risk for worse COVID-19 infection, yet an immune stimulation, such as vaccination, could re-activate…
- Conditions
- Rheumatoid Arthritis, Autoimmune Rheumatologic Disease, Systemic Lupus Erythematosus, Systemic Vasculitis
- Trial name
- COVBIRD (NCT05236491)
- Testing
- COVID-19 vaccine
- Where
- 2 sites in Canada
- Volunteers
- 287 people
- Sponsor
- Paul R Fortin
Multiple Myeloma
A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma
This study is to understand how well elranatamab (PF-06863135) may be used for relapsed refractory multiple myeloma (RRMM). Sometimes MM might improve at first, but then gets resistant to the treatment and starts growing again…
- Trial name
- NCT05932290
- Testing
- Elranatamab, Standard of care
- Where
- United States
- Volunteers
- 514 people
- Sponsor
- Pfizer
HIV, Human Immunodeficiency Virus
Text Education About Cardiovascular Health and HIV (TEACH-HIV)
The overall objective is to evaluate the efficacy of educational text messages to reduce cardiovascular risk among persons living with HIV (PLWH).
- Conditions
- HIV, Human Immunodeficiency Virus, Cardiovascular Diseases, Atherosclerosis
- Trial name
- NCT05642858
- Testing
- Digital Educational Messaging
- Where
- 2 sites in United States
- Volunteers
- 260 people
- Sponsor
- University of California, San Francisco
Temporal Arteritis
Aetiology of TemporaL Arteritis Study
Giant Cell Arteritis (GCA) is the most common vasculitis and has significant morbidity in terms of blindness, stroke, and tissue necrosis.
- Trial name
- ATLAS (NCT02584517)
- Sponsor
- University of Oxford
Hereditary Angioedema
A Phase III, Crossover Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)
This study is a randomized, double-blind, placebo-controlled, phase III, three-way crossover clinical trial evaluating the efficacy and safety of KVD900, in the treatment of hereditary angioedema attacks in adolescent and adult…
- Trial name
- NCT05259917
- Testing
- KVD900 600 mg, KVD900 300 mg
- Where
- 66 sites in United States, Australia and 19 more
- Volunteers
- 136 people
- Sponsor
- KalVista Pharmaceuticals, Ltd.
Giant Cell Arteritis (GCA)
oPtic Nerve Sheath Evaluation in gianT Cell aRtheritis by UltraSound
The purpose of this study is to evaluate whether the measure of the optic nerve sheath is a reliable diagnostic marker for giant cell arteritis
- Trial name
- PETRUS (NCT07001059)
- Testing
- orbital ultrasound
- Where
- 9 sites in France
- Volunteers
- 190 people
- Sponsor
- Hôpital NOVO
Multiple Myeloma
BiRd vs. Rd as Initial Therapy in Multiple Myeloma
This is a randomized, open-label, phase III study to investigate the efficacy of combination therapy with an induction phase utilizing a combination clarithromycin (Biaxin®), lenalidomide (Revlimid®), dexamethasone (Decadron®)…
- Trial name
- BiRd vs Rd (NCT02516696)
- Testing
- Clarithromycin, Lenalidomide, Dexamethasone
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Weill Medical College of Cornell University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.